

Long-Term Efficacy and Safety Extension Study of BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome)

Phoenix, Arizona, United States
Oakland, California, United States
Orange, California, United States
Wilmington, Delaware, United States
Washington, District of Columbia, United States
Orlando, Florida, United States
Honolulu, Hawaii, United States
Chicago, Illinois, United States
New York, New York, United States
Seattle, Washington, United States
Cordoba, , Argentina
Campina Grade, , Brazil
Porto Alegre, , Brazil
Rio de Janeiro, , Brazil
Montreal, , Canada
Sherbrooke, , Canada
Toronto, , Canada
Bogota, , Colombia
Copenhagen, , Denmark
Lyon, , France
Marseille, , France
Paris, , France
Paris, , France
Mainz, , Germany
Monza, , Italy
Tokyo, , Japan
Seoul, , Korea, Republic of
Amsterdam, , Netherlands
Oslo, , Norway
Coimbra, , Portugal
Lisbon, , Portugal
Doha, , Qatar
Riyadh, , Saudi Arabia
Santiago de Compostela, , Spain
Taipei, , Taiwan
Ankara, , Turkey
Belfast, , United Kingdom
Birmingham, , United Kingdom
Birmingham, , United Kingdom
London, , United Kingdom
London, , United Kingdom
London, , United Kingdom
Manchester, , United Kingdom

This Phase 3 extension study will evaluate the long-term efficacy and safety of BMN 110 2.0 mg/kg/week and/or BMN 110 2.0 mg/kg/every other week in patients with mucopolysaccharidosis IVA (Morquio A Syndrome).